Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL-Reference-Cited by-同舟云学术

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Published:2015-10-15 Issue:16 Volume:126 Page:1893-1901
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Offner Fritz¹,Samoilova Olga²,Osmanov Evgenii³,Eom Hyeon-Seok⁴,Topp Max S.⁵,Raposo João⁶,Pavlov Viacheslav⁷,Ricci Deborah⁸,Chaturvedi Shalini⁹,Zhu Eugene⁸,van de Velde Helgi¹⁰,Enny Christopher⁸,Rizo Aleksandra⁸,Ferhanoglu Burhan¹¹

Affiliation:

1. Department of Hematology, University Hospital Ghent, Ghent, Belgium;

2. Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation;

3. N.N. Blokhin Cancer Research Center, Russian Academy of National Sciences, Moscow, Russian Federation;

4. National Cancer Center, Goyang Gyeonggi, Republic of Korea;

5. Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany;

6. Servicio de Hematologia, Santa Maria Hospital, Lisbon, Portugal;

7. Medical Scientific Radiology Center, Obninsk, Russian Federation;

8. Janssen Research & Development, LLC, Raritan, NJ;

9. Janssen Research & Development, LLC, Spring House, PA;

10. Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium; and

11. Department of Internal Medicine, Division of Hematology, Koc University, Istanbul, Turkey

Abstract

Key Points This trial evaluated frontline VR-CAP and R-CHOP therapy for patients with centrally confirmed non-GCB DLBCL. There was no significant improvement in response rates or long-term outcomes with VR-CAP vs R-CHOP in previously untreated non-GCB DLBCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/16/1893/1389144/1893.pdf

Reference84 articles.

1. Diffuse large B-cell lymphoma: current strategies and future directions.;Cultrera;Cancer Contr,2012

2. Novel treatment strategies for aggressive non-Hodgkin’s lymphoma.;Fayad;Expert Opin Pharmacother,2006

3. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.;Alizadeh;Nature,2000

4. Stromal gene signatures in large-B-cell lymphomas.;Lenz;N Engl J Med,2008

5. Molecular pathogenesis of diffuse large B-cell lymphoma.;Lossos;J Clin Oncol,2005

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-07-03

2. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

3. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up;Clinical Lymphoma Myeloma and Leukemia;2024-02

4. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials;Annals of Hematology;2024-01-08

5. Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials;Leukemia & Lymphoma;2024-01-05